tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

CLColgate-Palmolive

Consumer staples · Cosmetics · NYSE

Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. 10-K, Item 1

CL quote by TradingView
Employees
33,600
Headquarters
New York, NY
CEO
Noel R. Wallace
Next results
around Jan 29, 2027
Compare with peers → Embed
All key numbers (42, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)2.57Sales (ttm)21.3BNet income (ttm)2.1BSales growth+1.4%EPS growth-25.1%Sales Q/Q+4.6%
Free cash flow3.8BGross margin60.6%Oper. margin14.9%Net margin9.6%FCF margin17.8%ROEn/m
ROA12.3%R&D / sales1.8%Dividend2.08Debt/Eqn/mCurr. ratio0.96Cash1.5B
Op. cash flow (ttm)4.4BEBITDA3.9BEBITDA margin19.3%Net debt5.7BQuick ratio0.65Interest cover12.38
ROIC32.7%Payout ratio79.1%Tax rate26.1%Stock pay / sales0.8%Shares out.794.9MShares Y/Y-1.5%
Book / share0.36Cash / share1.92Sales / share26.78Asset turnover1.27Inventory turns4.00Days sales out.30
Sales 3Y CAGR+4.3%Sales 5Y CAGR+4.4%EPS 3Y CAGR+7.3%EPS 5Y CAGR-3.5%Employees33,600Sales / employee633K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024
  • Operating margin narrowed to 16.2%21.2% → 16.2% · Operating income / revenue · 10-K ↗
What management wrote about it → · Every company →

CL against Consumer staples peers

Ten years, side by side → · All 34 →
GrowthProfitBalanceCleanInsiders
CLPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 34 companies, the better end on the right. Hover a dot for the company.

Sales growth
+1.4%22nd of 33 · median +2.1%
Net margin
9.6%16th of 33 · median 8.0%
Free cash flow margin
17.8%7th of 33 · median 10.7%
CL and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
CL Colgate-Palmolive$21.3B +1.4%60.6%9.6%-17.8%-
MO Altria$23.5B -3.1%63.3%34.5%-38.6%-
KDP Keurig Dr Pepper$23.1B +8.2%48.0%7.1%6.5%10.1%1.14
DLTR Dollar Tree$20.1B +10.4%38.6%8.0%47.1%9.9%0.86
CASY Casey's$18.7B +10.2%-4.1%18.9%3.5%0.59
GIS General Mills$18.3B -5.4%33.6%-4.9%-12.0%8.5%1.83

From $17.4B of sales to $2.2B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $10.4BRevenue to Cost of revenue: $7.0BGross profit to Operating profit: $3.3BGross profit to Operating expenses: $7.0BOperating profit to Net profit: $2.2BOperating profit to Tax & other: $1.2BOperating expenses to R&D: $307.0MOperating expenses to Sales, admin & other: $6.7B Revenue: $17.4B Revenue$17.4B +6% Y/Y Gross profit: $10.4B · 60% margin Gross profit$10.4B60% margin +4% Y/Y Cost of revenue: $7.0B · 40% of revenue Cost of revenue$7.0B40% of revenue Operating profit: $3.3B · 19% margin Operating profit$3.3B19% margin −14% Y/Y Operating expenses: $7.0B · 40% of revenue Operating expenses$7.0B40% of revenue Net profit: $2.2B · 12% margin Net profit$2.2B12% margin −20% Y/Y Tax & other: $1.2B · 7% of revenue Tax & other$1.2B7% of revenue R&D: $307.0M · 2% of revenue R&D$307.0M2% of revenue Sales, admin & other: $6.7B · 39% of revenue Sales, admin & other$6.7B39% of revenue

Swipe sideways for the whole flow →

From $18.0B of sales to $1.8B of profit

FY2022, from the 10-K income statement and revenue by segment
Oral Personal And Home Care to Revenue: $14.3BPet Nutrition to Revenue: $3.7BRevenue to Gross profit: $10.2BRevenue to Cost of revenue: $7.7BGross profit to Operating profit: $2.9BGross profit to Operating expenses: $7.4BOperating profit to Net profit: $1.8BOperating profit to Tax & other: $1.1BOperating expenses to R&D: $320.0MOperating expenses to Sales, admin & other: $7.0B Oral Personal And Home Care: $14.3B · 79% Oral Personal And Home…$14.3B79% Pet Nutrition: $3.7B · 21% Pet Nutrition$3.7B21% Revenue: $18.0B Revenue$18.0B +3% Y/Y Gross profit: $10.2B · 57% margin Gross profit$10.2B57% margin −1% Y/Y Cost of revenue: $7.7B · 43% of revenue Cost of revenue$7.7B43% of revenue Operating profit: $2.9B · 16% margin Operating profit$2.9B16% margin −13% Y/Y Operating expenses: $7.4B · 41% of revenue Operating expenses$7.4B41% of revenue Net profit: $1.8B · 10% margin Net profit$1.8B10% margin −18% Y/Y Tax & other: $1.1B · 6% of revenue Tax & other$1.1B6% of revenue R&D: $320.0M · 2% of revenue R&D$320.0M2% of revenue Sales, admin & other: $7.0B · 39% of revenue Sales, admin & other$7.0B39% of revenue

Swipe sideways for the whole flow →

From $19.5B of sales to $2.3B of profit

FY2023, from the 10-K income statement and revenue by segment
Oral Personal And Home Care to Revenue: $15.2BPet Nutrition to Revenue: $4.3BRevenue to Gross profit: $11.3BRevenue to Cost of revenue: $8.1BGross profit to Operating profit: $4.0BGross profit to Operating expenses: $7.3BOperating profit to Net profit: $2.3BOperating profit to Tax & other: $1.7BOperating expenses to R&D: $343.0MOperating expenses to SG&A: $7.0B Oral Personal And Home Care: $15.2B · 78% Oral Personal And Home…$15.2B78% Pet Nutrition: $4.3B · 22% Pet Nutrition$4.3B22% Revenue: $19.5B Revenue$19.5B +8% Y/Y Gross profit: $11.3B · 58% margin Gross profit$11.3B58% margin +11% Y/Y Cost of revenue: $8.1B · 42% of revenue Cost of revenue$8.1B42% of revenue Operating profit: $4.0B · 20% margin Operating profit$4.0B20% margin +38% Y/Y Operating expenses: $7.3B · 38% of revenue Operating expenses$7.3B38% of revenue Net profit: $2.3B · 12% margin Net profit$2.3B12% margin +29% Y/Y Tax & other: $1.7B · 9% of revenue Tax & other$1.7B9% of revenue R&D: $343.0M · 2% of revenue R&D$343.0M2% of revenue SG&A: $7.0B · 36% of revenue SG&A$7.0B36% of revenue

Swipe sideways for the whole flow →

From $20.1B of sales to $2.9B of profit

FY2024, from the 10-K income statement and revenue by segment
Oral Personal And Home Care to Revenue: $15.6BPet Nutrition to Revenue: $4.5BRevenue to Gross profit: $12.2BRevenue to Cost of revenue: $7.9BGross profit to Operating profit: $4.3BGross profit to Operating expenses: $7.9BOperating profit to Net profit: $2.9BOperating profit to Tax & other: $1.4BOperating expenses to R&D: $355.0MOperating expenses to SG&A: $7.5B Oral Personal And Home Care: $15.6B · 78% Oral Personal And Home…$15.6B78% Pet Nutrition: $4.5B · 22% Pet Nutrition$4.5B22% Revenue: $20.1B Revenue$20.1B +3% Y/Y Gross profit: $12.2B · 60% margin Gross profit$12.2B60% margin +7% Y/Y Cost of revenue: $7.9B · 40% of revenue Cost of revenue$7.9B40% of revenue Operating profit: $4.3B · 21% margin Operating profit$4.3B21% margin +7% Y/Y Operating expenses: $7.9B · 39% of revenue Operating expenses$7.9B39% of revenue Net profit: $2.9B · 14% margin Net profit$2.9B14% margin +26% Y/Y Tax & other: $1.4B · 7% of revenue Tax & other$1.4B7% of revenue R&D: $355.0M · 2% of revenue R&D$355.0M2% of revenue SG&A: $7.5B · 38% of revenue SG&A$7.5B38% of revenue

Swipe sideways for the whole flow →

From $20.4B of sales to $2.1B of profit

FY2025, from the 10-K income statement and revenue by segment
Oral Personal And Home Care to Revenue: $15.8BPet Nutrition to Revenue: $4.6BRevenue to Gross profit: $12.3BRevenue to Cost of revenue: $8.1BGross profit to Operating profit: $3.3BGross profit to Operating expenses: $8.9BOperating profit to Net profit: $2.1BOperating profit to Tax & other: $1.2BOperating expenses to R&D: $366.0MOperating expenses to Sales, admin & other: $8.6B Oral Personal And Home Care: $15.8B · 77% Oral Personal And Home…$15.8B77% Pet Nutrition: $4.6B · 23% Pet Nutrition$4.6B23% Revenue: $20.4B Revenue$20.4B +1% Y/Y Gross profit: $12.3B · 60% margin Gross profit$12.3B60% margin +1% Y/Y Cost of revenue: $8.1B · 40% of revenue Cost of revenue$8.1B40% of revenue Operating profit: $3.3B · 16% margin Operating profit$3.3B16% margin −23% Y/Y Operating expenses: $8.9B · 44% of revenue Operating expenses$8.9B44% of revenue Net profit: $2.1B · 10% margin Net profit$2.1B10% margin −26% Y/Y Tax & other: $1.2B · 6% of revenue Tax & other$1.2B6% of revenue R&D: $366.0M · 2% of revenue R&D$366.0M2% of revenue Sales, admin & other: $8.6B · 42% of revenue Sales, admin & other$8.6B42% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

3 of 4
  • ✓
    Net margin above the peer median9.6% vs 8.0%
  • !
    Gross margin down over 5 years60.8% → 60.1%
  • ✓
    Return on equity above 15%712.8%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 16.1% → 10.5%

Balance sheet

2 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 12.4× interest expense
  • !
    Debt larger than equityDebt / equity 24.94 on the latest balance sheet (peer median 0.82)
  • !
    Current ratio below 1Current ratio 0.96
  • ✓
    Net debt under 3 years of free cash flow$5.5B net debt, 1.5 years
Debt / equity at each year end, FY2016 to FY2025: 64.85 → 145.17
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$3.6B last year
  • ✓
    Share count down over 5 years−5.6%
  • ✓
    Dividend per share up over 5 years$1.75 → $2.08
  • ✓
    Cash from operations above net income$4.2B vs $2.1B
Free cash flow, FY2016 to FY2025: 2.5B → 3.6B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 30, 2026 · schedule of Dec 31, 2025
Debt: $7.2B Debt$7.2B Long-term debt: $7.2B · 87% Long-term debt$7.2B · 87% Due within a year: $1.1B · 13% Due within a year$1.1B · 13% Next 12 months: $1.1B · 13% Next 12 months$1.1B · 13% Year 2: $523.0M · 6% Year 2$523.0M · 6% Year 3: $615.0M · 7% Year 3$615.0M · 7% Year 4: $591.0M · 7% Year 4$591.0M · 7% Year 5: $500.0M · 6% Year 5$500.0M · 6% After year 5: $4.5B · 54% After year 5$4.5B · 54%

The debt note's own lines, 2025-11-30

Line, as the company names itKindRateFixed or floatingAmount
Ten year Notes at 3.250 Percent NumberNotes and bonds3.25%not stated$600.0M

From the debt note in the 10-K's XBRL (0000021665-26-000006), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 20.4B Net income 2.1B
FY2016 revenue 15.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-19-000003 FY2016 net income 2.4B · NetIncomeLoss, 0000021665-19-000003 15.2B FY2016 FY2017 revenue 15.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-20-000004 FY2017 net income 2.0B · NetIncomeLoss, 0000021665-20-000004 15.5B FY2017 FY2018 revenue 15.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-21-000007 FY2018 net income 2.4B · NetIncomeLoss, 0000021665-21-000007 15.5B FY2018 FY2019 revenue 15.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-22-000003 FY2019 net income 2.4B · NetIncomeLoss, 0000021665-22-000003 15.7B FY2019 FY2020 revenue 16.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-23-000007 FY2020 net income 2.7B · NetIncomeLoss, 0000021665-23-000007 16.5B FY2020 FY2021 revenue 17.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-24-000003 FY2021 net income 2.2B · NetIncomeLoss, 0000021665-24-000003 17.4B FY2021 FY2022 revenue 18.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-25-000008 FY2022 net income 1.8B · NetIncomeLoss, 0000021665-25-000008 18.0B FY2022 FY2023 revenue 19.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-26-000006 FY2023 net income 2.3B · NetIncomeLoss, 0000021665-26-000006 19.5B FY2023 FY2024 revenue 20.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-26-000006 FY2024 net income 2.9B · NetIncomeLoss, 0000021665-26-000006 20.1B FY2024 FY2025 revenue 20.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000021665-26-000006 FY2025 net income 2.1B · NetIncomeLoss, 0000021665-26-000006 20.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

CL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue20.4B
FY2016: 15.2BFY2017: 15.5BFY2018: 15.5BFY2019: 15.7BFY2020: 16.5BFY2021: 17.4BFY2022: 18.0BFY2023: 19.5BFY2024: 20.1BFY2025: 20.4B FY2017FY2019FY2021FY2023FY2025
Net income2.1B
FY2016: 2.4BFY2017: 2.0BFY2018: 2.4BFY2019: 2.4BFY2020: 2.7BFY2021: 2.2BFY2022: 1.8BFY2023: 2.3BFY2024: 2.9BFY2025: 2.1B FY2017FY2019FY2021FY2023FY2025
Free cash flow3.6B
FY2016: 2.5BFY2017: 2.5BFY2018: 2.6BFY2019: 2.8BFY2020: 3.3BFY2021: 2.8BFY2022: 1.9BFY2023: 3.0BFY2024: 3.5BFY2025: 3.6B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.63
FY2016: 2.72FY2017: 2.28FY2018: 2.75FY2019: 2.75FY2020: 3.14FY2021: 2.55FY2022: 2.13FY2023: 2.77FY2024: 3.51FY2025: 2.63 FY2017FY2019FY2021FY2023FY2025
Dividend per share2.08
FY2016: -FY2017: 1.59FY2018: 1.66FY2019: 1.71FY2020: 1.75FY2021: 1.79FY2022: 1.86FY2023: 1.91FY2024: 2.48FY2025: 2.08 FY2017FY2019FY2021FY2023FY2025
Diluted shares811.1M
FY2016: 898.4MFY2017: 887.8MFY2018: 873.0MFY2019: 861.1MFY2020: 859.3MFY2021: 848.3MFY2022: 838.8MFY2023: 829.2MFY2024: 823.2MFY2025: 811.1M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Oral Personal And Home Care 15.8B77.4% +1.0%
Pet Nutrition 4.6B22.6% +2.9%

10-K 0000021665-26-000006, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue15.2B15.5B15.5B15.7B16.5B17.4B18.0B19.5B20.1B20.4B
Cost of revenue6.1B6.2B6.3B6.4B6.5B7.0B7.7B8.1B7.9B8.1B
Gross profit9.1B9.3B9.2B9.3B10.0B10.4B10.2B11.3B12.2B12.3B
R&D289.0M285.0M277.0M281.0M290.0M307.0M320.0M343.0M355.0M366.0M
SG&A5.1B5.4B5.4B5.6B6.0B6.4B6.6B7.2B7.7B7.9B
Operating income4.0B3.7B3.7B3.6B3.9B3.3B2.9B4.0B4.3B3.3B
Interest expense155.0M156.0M195.0M193.0M184.0M120.0M167.0M287.0M292.0M267.0M
Pretax income3.7B3.5B3.5B3.3B3.6B3.1B2.7B3.4B4.0B3.1B
Income tax1.2B1.3B906.0M774.0M787.0M749.0M693.0M937.0M907.0M798.0M
Net income2.4B2.0B2.4B2.4B2.7B2.2B1.8B2.3B2.9B2.1B
EPS (diluted)2.722.282.752.753.142.552.132.773.512.63
Diluted shares898.4M887.8M873.0M861.1M859.3M848.3M838.8M829.2M823.2M811.1M
Depreciation & amortization443.0M475.0M511.0M519.0M539.0M556.0M545.0M567.0M605.0M630.0M
EBITDA4.4B4.2B4.2B4.1B4.4B3.9B3.4B4.6B4.9B3.9B
Gross margin60.0%60.0%59.4%59.4%60.8%59.6%57.0%58.2%60.5%60.1%
Operating margin26.0%24.0%23.8%22.6%23.6%19.1%16.1%20.5%21.2%16.2%
Net margin16.1%13.1%15.4%15.1%16.4%12.4%9.9%11.8%14.4%10.5%
Revenue growth-+1.7%+0.6%+1.0%+5.0%+5.8%+3.1%+8.3%+3.3%+1.4%
EPS growth--16.2%+20.6%0.0%+14.2%-18.8%-16.5%+30.0%+26.7%-25.1%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash1.3B1.5B726.0M883.0M888.0M832.0M775.0M966.0M1.1B1.3B
Short-term investments-------179.0M160.0M107.0M
Receivables1.4B1.5B1.4B1.4B1.3B1.3B1.5B1.6B1.5B1.7B
Inventory1.2B1.2B1.2B1.4B1.7B1.7B2.1B1.9B2.0B2.0B
Current assets4.3B4.6B3.8B4.2B4.3B4.4B5.1B5.3B5.3B5.7B
Property & equipment3.8B4.1B3.9B3.8B3.7B3.7B4.3B4.6B4.4B4.7B
Goodwill2.1B2.2B2.5B3.5B3.8B3.3B3.4B3.4B3.3B3.1B
Total assets12.1B12.7B12.2B15.0B15.9B15.0B15.7B16.4B16.0B16.3B
Accounts payable1.1B1.2B1.2B1.2B1.4B1.5B1.6B1.7B1.8B2.1B
Current liabilities3.3B3.4B3.3B4.0B4.4B4.1B4.0B4.7B5.8B6.9B
Total debt6.5B6.6B6.4B7.6B7.3B7.2B8.8B8.2B7.0B7.8B
Total liabilities12.1B12.4B12.0B14.5B14.8B14.1B14.9B15.4B15.5B16.0B
Shareholders' equity-243.0M-60.0M-102.0M117.0M743.0M609.0M401.0M609.0M212.0M54.0M
Retained earnings19.9B20.5B21.6B22.5B23.7B24.4B24.6B25.3B26.1B26.6B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow3.1B3.1B3.1B3.1B3.7B3.3B2.6B3.7B4.1B4.2B
Capital spending593.0M553.0M436.0M335.0M409.0M567.0M696.0M705.0M561.0M564.0M
Free cash flow2.5B2.5B2.6B2.8B3.3B2.8B1.9B3.0B3.5B3.6B
Stock-based pay (added back)123.0M127.0M109.0M100.0M107.0M135.0M125.0M122.0M135.0M155.0M
Buybacks1.3B1.4B1.2B1.2B1.5B1.3B1.3B1.1B1.7B1.2B
Acquisitions5.0M0728.0M1.7B353.0M0809.0M00293.0M
Debt raised7.4B4.8B7.2B8.1B------
Debt repaid7.3B4.8B7.4B6.6B------
Investing cash flow-499.0M-471.0M-1.2B-2.1B-779.0M-592.0M-1.6B-742.0M-534.0M-817.0M
Financing cash flow-2.2B-2.5B-2.7B-870.0M-2.9B-2.8B-952.0M-2.8B-3.4B-3.3B
Dividend per share-1.591.661.711.751.791.861.912.482.08

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)123.0M127.0M109.0M100.0M107.0M135.0M125.0M122.0M135.0M155.0M
Stock-based pay / revenue0.8%0.8%0.7%0.6%0.6%0.8%0.7%0.6%0.7%0.8%
Operating lease cost--169.0M169.0M155.0M142.0M138.0M136.0M144.0M152.0M
Operating lease cash paid---202.0M193.0M173.0M169.0M171.0M132.0M151.0M
Right-of-use assets---502.0M521.0M527.0M478.0M491.0M529.0M531.0M
Operating lease liabilities---636.0M613.0M588.0M505.0M515.0M563.0M566.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on CL in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CL/export.csv") into a cell.